Trials / Recruiting
RecruitingNCT06782334
AMT-116 in Patients with Solid Tumors
Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Multitude Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT-116 | AMT-116 is an antibody Drug Conjugate (ADC) |
Timeline
- Start date
- 2024-05-07
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
- First posted
- 2025-01-17
- Last updated
- 2025-01-17
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06782334. Inclusion in this directory is not an endorsement.